BRAF V600_K601DELINSD

CI-VAR-00004583Explore in graph →CIViC 1658

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cutaneous Melanoma1
BRAF V600_K601DELINSD	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4789 In a stage IV cutaneous nodular thoracic melanoma patient with pulmonary, liver and brain metastases, harboring a BRAF V600_K601delinsD mutation, stable disease to vemurafenib monotherapy was reported… (full text at CIViC) PMID 25265970 · Trudel et al., 2014 · Open in CIViC	civic
Melanoma1
BRAF V600_K601DELINSD	Vemurafenib	Predictive	C	Supports Sensitivity Response	—	submitted	EID4790 In a stage IIIc melanoma patient harboring BRAF V600_K601delinsD mutation, response to vemurafenib monotherapy was reported. The patient achieved a reduction in the size of axillary and pectoral subcu… (full text at CIViC) PMID 24108467 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.